Infusion-related reactions to rituximab: frequency, mechanisms and predictors
Author:
Affiliation:
1. Département d’Hématologie Clinique, CHRU de Montpellier, Montpellier, France;
2. CNRS UMR 5235, Université de Montpellier, Montpellier, France
Funder
not funded
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2019.1562905
Reference53 articles.
1. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
2. Rituximab in chronic lymphocytic leukemia
3. Rituximab: Mechanism of action and resistance
4. Rituximab: Mechanism of Action
5. From the bench to the bedside: ways to improve rituximab efficacy
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia;Frontiers in Pharmacology;2024-01-26
2. Adverse events following rituximab therapy in pemphigus patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
3. Rituximab use in paediatric nephrology practice in Türkiye: TRTX;Nephrology;2023-12-19
4. Immunobiological Therapies in Rheumatoid Arthritis: Mechanisms of Action and Future Perspectives;Trends and Innovations in Energetic Sources, Functional Compounds and Biotechnology;2023-12-01
5. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19;Journal of Virology;2023-11-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3